Biomarkers

Unlock the Full Power of Biomarkers

Expert biomarker bioanalysis –
from analytical strategies to data delivery.

Talk To Us Now

Helping drug developers unlock actionable insights, accelerate clinical decisions, and bring innovative therapies to patients with confidence.

Biomarkers are playing an ever-increasing role in discovery and development of drugs, and have a wide range of potential clinical utilities.

Resolian provides a highly accomplished team with extensive experience in biomarker development and analysis, and the skills and expertise to build you a right-fit biomarker solution.

Spanning all phases of drug development, Resolian’s personalized biomarker solutions help drive your development program to market.

Reach out to us directly to learn more about Resolian’s Biomarker services.

Resolian – the biomarker specialists.

Start here

Your Partner for Biomarker Bioanalysis

We deliver end-to-end biomarker support – combining analytical precision with translational expertise to accelerate your program.

Our Biomarker Expertise

  • ELISA, MSD, Quanterix, Gyros and ELLA for protein biomarker quantification
  • LC-MS/MS and LC-HRAM for small and large molecular biomarkers

  • RT-qPCR and ddPCR for mRNA and miRNA biomarkers

  • Comprehensive flow cytometry capabilities for quantitative and qualitative biomarker assessment

  • Oligonucleotide based protein biomarkers
    (PCSK9, AGT, SOD1, Activin E, ALK7, GRB14, etc)

  • Ready to use in-house established methods for common targets including cytokines

  • End-to-end support: from Context of Use assay development to regulatory-ready data packages

Your Biomarker Partner

  • Strategic partners, not just a lab – we help design your entire biomarker analytical strategy

  • Flexible platforms tailored to your molecule and regulatory needs

  • Global network of bioanalytical labs with deep submission experience

  • Assessing new technologies and approaches

  • Scientists embedded in key industry forums – ensuring methods reflect the latest regulatory thinking

Biomarker Services

  • Custom method development and assay validation
  • Transfer of proprietary assays
  • Commercial kit qualification
Alliance Pharma 063

Technology Platforms

Immunoassay:

Chromatography:

Lab Expertise

Our Fordham site is Certified Service Provider Status on Ella™ Platform

Our Fordham and Malvern sites are both a Gyrolab Certified CRO Partner.

Gyrolab Certified
Bio Techne CSP logo certified service provider badge 2color

Ready to advance your biomarker program?

Partner with the global biomarker specialist that delivers scientific excellence, regulatory expertise, and seamless project management.

start your project today
Download Biomarker Assay List

Our Biomarker Resources

Plasma Protein Binding Assessment for Highly Protein-Bound Compounds | ICH M12 | Resolian

Case Studies

Measuring What Matters: High-Precision Plasma Protein Binding Assessment for Highly Bound Compounds Under ICH M12

Learn more
Solving Carboplatin: A Novel LC-MS/MS Assay for Intact Drug Quantitation in Human Plasma

Case Studies

Solving Carboplatin: A Novel LC-MS/MS Assay for Intact Drug Quantitation in Human Plasma

Learn more
Ultra-Low B Cell Detection: Flow Cytometry Method Validation to 10 cells/μL | Resolian Case Study

Case Studies

Ultra-Low B Cell Detection: Flow Cytometry Method Validation to 10 cells/μL

Learn more
When AI Meets Experimental Biology: Supporting Breakthrough Peptide Research

Blog, Publications

When AI Meets Experimental Biology: Supporting Breakthrough Peptide Research

Learn more
Developing and Validating a Simple, Rapid LC-MS/MS Method for Semaglutide in Human Plasma

Case Studies

Developing and Validating a Simple, Rapid LC-MS/MS Method for Semaglutide in Human Plasma

Learn more
Overcoming Bioanalytical Challenges in siRNA Oligonucleotide Quantitation by LC-MS

Case Studies

Overcoming Bioanalytical Challenges in siRNA Oligonucleotide Quantitation by LC-MS

Learn more
Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.